A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-3083|32|1|145-151

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.32, Iss.1, 2018-01, pp. : 145-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4268-4276

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow‐up: A randomized blinded controlled trial

By  

LASERS IN SURGERY AND MEDICINE, Vol. 47, Iss. 2, 2015-02 ,pp. : 173-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A phase 1, randomized controlled study

By  

EPILEPSIA, Vol. 55, Iss. 12, 2014-12 ,pp. : 1934-1943

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects

By Watabe Mitsuo   Cheng Yi-Fang   Nilsson Dag   Itoh Yohji   Kumagai Yuji  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1849-1857

Informa Healthcare

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite